GHRP-2

GHRP-2 is a synthetic hexapeptide from the first generation of growth hormone–releasing peptides, developed in the 1980s and 1990s before the natural signal for the receptor they act on had been identified. That sequence of events is worth noting: these compounds were found by screening for an effect, and the hormone they were imitating — ghrelin — was only discovered afterwards, in 1999.

Among peptides at this receptor it is one of the more potent, producing a larger growth hormone response than its close relative GHRP-6 at comparable amounts. That potency is why it remained in research use, and it was taken some distance into clinical evaluation as a diagnostic agent for assessing pituitary function.

Its response is also broader. Along with growth hormone, it raises cortisol and prolactin to a measurable degree. In a diagnostic setting that is tolerable; in an experiment isolating one pathway it is a confounder, and it is the specific problem later selective compounds were designed to avoid.

• Discovered before its receptor: It is a documented case of a synthetic compound revealing that a receptor and a natural hormone must exist. The search it prompted led to the identification of ghrelin, which is a notable piece of endocrine history.

• Potency as a benchmark: It produces one of the larger growth hormone responses in its class, which makes it the upper reference point when the potency of newer secretagogues is being assessed.

• Pituitary function assessment: It was evaluated as a diagnostic tool for probing whether the pituitary can release growth hormone on demand, so part of its literature concerns measurement rather than effect.

• Off-target hormone movement: The cortisol and prolactin response is itself studied, because understanding why a molecule at this receptor also engages those pathways is what allowed more selective successors to be designed.

The pituitary releases growth hormone when instructed, and two separate instructions reach it. GHRH arrives from the hypothalamus as part of the growth axis. Ghrelin arrives from the stomach and reflects feeding state. GHRP-2 imitates the second: it binds the ghrelin receptor and the cell responds as though a hunger signal had arrived.

That release runs through a different internal pathway from the GHRH one, which is why the two produce a bigger response together than separately. It is also why this class does not simply duplicate a GHRH analogue. The cell is being pushed by two mechanisms rather than harder by one, and the resulting pattern of release differs.

The off-target effects follow from shape. The ghrelin receptor sits within a family of structurally similar receptors, and a molecule that fits one will often fit another; the cortisol and prolactin rise reflects engagement of pathways beyond the intended one. Whether that matters depends entirely on the experiment — fatal to a study isolating growth hormone, irrelevant to one measuring maximum pituitary capacity.

The core pharmacology is solid and was worked out in peer-reviewed research over three decades. That GHRP-2 raises growth hormone in humans, that it acts at the ghrelin receptor, and that it also moves cortisol and prolactin are all established findings from controlled studies, many conducted while it was being evaluated diagnostically.

It has no marketing authorisation, its development was not completed, and it is supplied for laboratory research only. The published work measures the hormone response, and that is what it is used for: it produces one of the larger growth hormone responses in its class, which makes it the upper reference point when newer secretagogues are assessed.

GHRP-6 is the nearest relative, differing mainly in potency and in a considerably stronger appetite response — the two are usually read together as the pair that defined this class. Ipamorelin is the selective successor, and the reason it exists is visible in the off-target profile of these two.

CJC-1295 acts on the other receptor on the same pituitary cell, and combinations across the two families are a standard topic in this literature because the mechanisms are genuinely independent.